Samsung Bioepis has begun phase 1 clinical trial of the 10th biosimilar pipeline SB17. SB17 is a biosimilar for Stelara (Ustekinumab).

Samsung Bioepis launched Phase 1 in February to confirm the pharmacokinetics, safety, and immunogenicity of SB17 for 201 healthy volunteers in France.

Stelara is a treatment for autoimmune diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis sold by Johnson & Johnson in the United States. The volume of global sales in 2020 is about ₩8.4 trillion.

Samsung Bioepis was founded in 2012, and has developed three types of autoimmune diseases (SB2: biosimilar for Remicade, SB4: biosimilar for Enbrel, SB5: bi